bioAffinity Technologies, Inc. - What You Need to Know

Thinking about investing in bioAffinity Technologies? It is exciting to look at new biotech companies, but you must look past the science and focus on the business. Here is a breakdown of what you need to know.

1. What does this company actually do?

BioAffinity focuses on early-stage lung cancer diagnostics. They developed a non-invasive test called CyPath® Lung. Unlike genetic tests that look for DNA mutations, CyPath® Lung uses flow cytometry to analyze cells in a patient’s phlegm. The company uses a special compound that binds to cancer cells, making them "light up" under a microscope. This helps doctors identify cancer in high-risk patients, potentially helping them decide if a patient needs an invasive biopsy or just monitoring.

2. How do they make money?

The company is in the early stages of selling CyPath® Lung as a Laboratory Developed Test. They earn money by charging doctors and clinics for processing these tests. However, the company is not yet profitable. Operating expenses—mostly for research, development, and lab costs—far exceed their revenue. They have a history of losses and cannot predict if or when they will become profitable.

3. What’s happening with this new stock offering?

The company plans to raise about $3.4 million by selling new shares.

The Reality of Issuing More Shares: When you buy into this offering at $5.48 per share, you face "dilution." This means the company is issuing more shares, which reduces your ownership percentage. Before this offering, the company’s net tangible book value—the actual value of assets minus debts—was negative. After issuing these new shares, the book value will be about $0.76 per share.

This means for every $5.48 you invest, the underlying book value of your shares is much lower than the price you paid. The company notes an "immediate dilution" of $4.72 per share for new investors. You are essentially paying a premium to provide the company with cash, while your individual "slice" of the company's assets remains small.

4. What are the main risks?

Investing in small biotech companies is high-risk. BioAffinity faces several specific hurdles:

• Nasdaq Listing Compliance: The company has received warnings from Nasdaq for failing to meet minimum bid price and stockholders’ equity requirements. There is no guarantee they will stay listed, and being removed from the exchange could make it harder to sell your shares.
• Financial Health: The company does not have enough cash to fund long-term operations. They rely on selling more stock to pay for research and sales. They will need more money in the future, which will likely lead to more shares being issued and further dilution for you.
• Market Volatility: As a small company, BIAF stock price can swing wildly. The company warns that significant price drops could lead to shareholder lawsuits, which would further strain their finances.

5. Who's running the company?

Maria Zannes serves as President and CEO. Her background is in law, public policy, and business management rather than clinical research. This leadership choice reflects the company’s goal: moving from a research-focused group to a business capable of handling the regulatory and sales challenges of the diagnostic market.

6. Where will it trade?

The company trades on the Nasdaq under the ticker symbol BIAF.

Final Thought for Investors: Before you commit any capital, ask yourself if you are comfortable with the high level of risk associated with early-stage biotech. Because the company is not yet profitable and relies on selling more shares to keep the lights on, your investment could be subject to significant dilution and price swings.

Disclaimer: I am an AI, not a financial advisor. This company faces significant regulatory and financial hurdles. Small biotech stocks are very volatile. Never invest money you cannot afford to lose, and always read the official SEC filings before making a decision.